Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D4OW
|
|||
| Drug Name |
PMID25435285-Compound-15
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ELI LILLY AND COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15Cl2NO6
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1COC2C(C3C(C3C2(C(=O)O)N)C(=O)O)O)Cl)Cl
|
|||
| InChI |
1S/C15H15Cl2NO6/c16-6-2-1-5(3-7(6)17)4-24-12-11(19)8-9(13(20)21)10(8)15(12,18)14(22)23/h1-3,8-12,19H,4,18H2,(H,20,21)(H,22,23)/t8-,9-,10-,11-,12+,15+/m0/s1
|
|||
| InChIKey |
WNOZOUHFGZKGNT-ANYOLZDRSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Antagonist | [1] |
| Metabotropic glutamate receptor 3 (mGluR3) | Target Info | Antagonist | [1] | |
| Target's Patent Info | Metabotropic glutamate receptor 2 (mGluR2) | Target's Patent Info | [1] | |
| Metabotropic glutamate receptor 3 (mGluR3) | Target's Patent Info | [1] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.